Nuclea Biotechnologies (Pittsfield, MA) a commercial-stage diagnostic company focused on in vitro companion diagnostic assays based on gene and protein expression profiles and biomarkers associated with an individual’s tumor or specific disease state, closed a $3.4M Series B financing bringing the total round to $9.8M. Participants were not identified.

Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.